Athira Pharma Inc. (NASDAQ:ATHA) stock is trading higher on Thursday, with a session volume of 57.29 million compared to the average volume of 30.94 thousand as per data from Benzinga Pro.Athira Pharma on Thursday agreed to acquire the rights for the development and commercialization of lasofoxifene, a clinical asset in a potentially registrational Phase 3 trial.The ongoing Phase 3 ELAINE-3 clinical trial is greater than 50% enrolled, with data expected in mid-2027.Athira has acquired an exclusive global li ...

Athira Pharma, Inc. (ATHA) shares surged 69.53 percent, gaining $2.88 to trade at $7.01 on Thursday, after the clinical-stage biopharmaceutical company announced an agreement to acquire global development and commercialization rights to lasofoxifene, a Phase 3 ready asset for metastatic breast cancer. The stock was trading at $7.01, up sharply from a previous close of $4.14 on the Nasdaq. Shares opened at $7.22 and moved within a day's range of $6.77 to $8.35. Trading volume spiked to about 53.19 million s ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.The Dow traded up 0.44% to 48,097.08 while the NASDAQ jumped 1.08% to 22,938.56. The S&P 500 also rose, gaining, 0.76% to 6,772.76.Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend YieldsLeading and Lagging SectorsConsumer discretionary shares rose by 2% on Thursday.In trading on Thursday, energy stocks fell by 0.5%.Top Headlin ...

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 400 points on Thursday.The Dow traded up 0.84% to 48,289.58 while the NASDAQ jumped 1.53% to 23,040.25. The S&P 500 also rose, gaining, 1.09% to 6,794.36.Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend YieldsLeading and Lagging SectorsConsumer discretionary shares rose by 1.6% on Thursday.In trading on Thursday, energy stocks fell by 0.8%.Top HeadlineAccenture ( ...

Lasofoxifene (Metastatic Breast Cancer) - The global metastatic ER+/HER2- breast cancer market is expected to grow from approximately $10.9 billion in 2025 to roughly $15.9 billion by 2029[23] - Lasofoxifene, combined with abemaciclib, demonstrated a potential best-in-class median Progression-Free Survival (PFS) of 13 months in a heavily pre-treated mESR1 population in the Phase 2 ELAINE-2 trial[26, 27, 50] - In the ELAINE-1 Phase 2 study, lasofoxifene delivered a median PFS of 24.2 weeks compared to 16.2 weeks with fulvestrant in ESR1-mutant breast cancer[48] - Approximately 70% of all breast cancers are ER+/HER2- subtype[23, 32] - Lasofoxifene reduced new onset breast cancer by 83% in a large prevention trial[30] - The ELAINE-3 registrational Phase 3 trial is ongoing, with topline results expected in mid-2027 and over 50% enrollment[16, 17, 57, 138, 139] - Assuming approximately 10% market penetration, lasofoxifene has a peak market sale potential of over $1 billion in the US market[81] ATH-1105 (ALS) - Approximately 225,000 people globally are affected by ALS, with roughly 33,000 cases in the US[98] - ATH-1105 is a CNS-penetrant positive modulator of HGF as a potential treatment for ALS[103] - A Phase 2 POC study in ALS is planned to start in the first half of 2026, with topline results expected in 2027[18, 19, 140, 141] Financial - A PIPE financing of up to $236 million, including $90 million upfront, provides cash runway through data readout and into 2028[137]

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-sta ...